Who
Stuart A. Randle
Director
Company insider
Files Form 4 as: Interim President and CEO, Teleflex; Director, Qxo Building Products; Director, Comera Life Sciences Holdings; Director, Decoy Therapeutics; Director, Specialized Health Products International.
In numbers
- Trades disclosed
- 165
- Buys
- 3
- Sells
- 18
- Bought
- $207K
- Sold
- $10.1M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 15 Feb 2006
- Last trade
- 8 Jun 2026
- Last filed
- 9 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jun 2026filed 9 Jun 2026 | TFX TeleflexMedical Devices | SEC FORM 4 Code A | —995 at $0.00 | filing |
| 8 Jun 2026filed 9 Jun 2026 | TFX TeleflexMedical Devices | SEC FORM 4 Code A | —4,663 at $0.00 | filing |
| 8 Jun 2026filed 9 Jun 2026 | TFX Teleflexoption or derivative · Medical Devices | SEC FORM 4 Code A | —2,192 at $0.00 | filing |
| 8 Jun 2026filed 9 Jun 2026 | TFX Teleflexoption or derivative · Medical Devices | SEC FORM 4 Code A | —2,192 at $0.00 | filing |
| 8 Jun 2026filed 9 Jun 2026 | TFX TeleflexMedical Devices | SEC FORM 4 Code A | —995 at $0.00 | filing |
| 8 Jun 2026filed 9 Jun 2026 | TFX TeleflexMedical Devices | SEC FORM 4 Code A | —4,663 at $0.00 | filing |
| 7 Jun 2026filed 9 Jun 2026 | TFX TeleflexMedical Devices | SEC FORM 4 Code F | $526K4,054 at $129.84 | filing |
| 7 Jun 2026filed 9 Jun 2026 | TFX TeleflexMedical Devices | SEC FORM 4 Code F | $526K4,054 at $129.84 | filing |
| 9 May 2026filed 12 May 2026 | TFX TeleflexMedical Devices | SEC FORM 4 Code F | $38K289 at $133.06 | filing |
| 9 May 2026filed 12 May 2026 | TFX TeleflexMedical Devices | SEC FORM 4 Code F | $38K289 at $133.06 | filing |
| 13 Jan 2026filed 15 Jan 2026 | TFX TeleflexMedical Devices | SEC FORM 4 Code A | —12,325 at $0.00 | filing |
| 13 Jan 2026filed 15 Jan 2026 | TFX TeleflexMedical Devices | SEC FORM 4 Code A | —12,325 at $0.00 | filing |
| 5 Aug 2025filed 7 Aug 2025 | TFX TeleflexMedical Devices | SEC FORM 4 Bought | $116K1,000 at $115.86 | filing |
| 9 May 2025filed 13 May 2025 | TFX Teleflexoption or derivative · Medical Devices | SEC FORM 4 Code A | —2,226 at $0.00 | filing |
| 9 May 2025filed 13 May 2025 | TFX TeleflexMedical Devices | SEC FORM 4 Code A | —1,051 at $0.00 | filing |
| 29 Apr 2025filed 29 Apr 2025 | Qxo Building Productsoption or derivative | SEC FORM 4 Code D | $2.1M16,489 at $124.35 | filing |
| 29 Apr 2025filed 29 Apr 2025 | Qxo Building Productsoption or derivative | SEC FORM 4 Code D | $174K1,400 at $124.35 | filing |
| 29 Apr 2025filed 29 Apr 2025 | Qxo Building Products | SEC FORM 4 Code D | $3.2M25,970 at $124.35 | filing |
| 16 Aug 2024filed 16 Aug 2024 | TFX Teleflexoption or derivative · Medical Devices | SEC FORM 4 Code M | —2,674 at $0.00 | filing |
| 16 Aug 2024filed 16 Aug 2024 | TFX TeleflexMedical Devices | SEC FORM 4 Code M | $324K2,674 at $121.00 | filing |
News
Contrasting Teleflex (NYSE:TFX) & Trinity Biotech (NASDAQ:TRIB)TFX · tickerreport.com · 16 Oct 2026
0 headlines in the last 90 days name Stuart A. Randle; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.